Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -0.83 Decreased by -312.82% | -0.29 Decreased by -186.21% |
| Aug 1, 24 | 0.14 Increased by +75.00% | -0.04 Increased by +450.00% |
| May 2, 24 | 1.40 Increased by +263.45% | -0.13 Increased by +1.18 K% |
| Feb 22, 24 | 2.39 Increased by +175.63% | -1.18 Increased by +302.54% |
| Nov 2, 23 | 0.39 Increased by +18.18% | -0.62 Increased by +162.90% |
| Aug 3, 23 | 0.08 Increased by +127.59% | -0.70 Increased by +111.43% |
| May 4, 23 | 0.39 Increased by +292.60% | -0.87 Increased by +144.28% |
| Feb 23, 23 | -3.16 Decreased by -1.36 K% | -0.64 Decreased by -393.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 59.85 M Decreased by -50.14% | -50.43 M Decreased by -295.24% | Decreased by -84.26% Decreased by -491.55% |
| Jun 30, 24 | 77.87 M Decreased by -48.07% | 8.98 M Increased by +76.14% | Increased by +11.54% Increased by +239.18% |
| Mar 31, 24 | 62.43 M Decreased by -65.10% | 90.22 M Increased by +288.76% | Increased by +144.51% Increased by +1.01 K% |
| Dec 31, 23 | -209.12 M Decreased by -319.85% | 157.56 M Increased by +176.04% | Decreased by -75.34% Increased by +65.41% |
| Sep 30, 23 | 120.03 M Decreased by -11.88% | 25.83 M Increased by +19.84% | Increased by +21.52% Increased by +35.99% |
| Jun 30, 23 | 149.95 M Increased by +8.97% | 5.10 M Increased by +126.81% | Increased by +3.40% Increased by +124.60% |
| Mar 31, 23 | 178.87 M Increased by +31.19% | 23.21 M Increased by +274.36% | Increased by +12.97% Increased by +232.91% |
| Dec 31, 22 | 95.12 M Decreased by -43.04% | -207.21 M Decreased by -1.37 K% | Decreased by -217.84% Decreased by -2.32 K% |